See today's BioWorld Science
To read the full story, subscribe or sign in.
Respiratory

FDA awards orphan drug designation to Alveogene’s gene therapy for SP-B deficiency

Dec. 3, 2024
Alveogene Ltd. has announced its novel inhaled gene therapy for lethal neonatal surfactant protein B (SP-B) deficiency, AVG-002, has been awarded orphan drug designation by the FDA.
BioWorld Science Regulatory Neonatal/pediatrics Respiratory Gene therapy FDA Orphan drug